Journal: Molecular Medicine

Article Title: Pharmacological postconditioning with Neuregulin-1 mimics the cardioprotective effects of ischaemic postconditioning via ErbB4-dependent activation of reperfusion injury salvage kinase pathway

doi: 10.1186/s10020-018-0040-7

Figure Lengend Snippet: Increased NRG-1 and activation of ErbB2/4 by both IP and NRG-1 in vivo. ( a ), Representative protein levels of NRG-1. ( b ), Semi-quantification of protein levels of NRG-1. ( c ), Representative protein levels of P-ErbB4 and T-ErbB4 by western blotting. ( d ), Semi-quantification of the density ratio of P-ErbB4/T-ErbB4. ( e ), Representative protein levels of P-ErbB2 and T-ErbB2. ( f ), Semi-quantification of protein levels of P-ErbB2/T-ErbB2.These protein levels were normalised to GAPDH. CON: control, IR: ischaemia-reperfusion, IP: ischaemic postconditioning, NRG-1: IR + NRG-1. Data are shown as the mean ± SEM ( n = 6). # p < 0.05 vs. CON, * p < 0.05 vs. IR

Article Snippet: Primary antibodies used in the experiment were as follows: 202 Thr/ 204 Tyr-P-ERK1/2, T-ERK1/2, 473 Ser-P-AKT, T-AKT (pan), 389 Thr-P-p70S6k, p70S6k, 172 Thr-P-AMPK, AMPK (rabbit monoclonal antibodies, Cell Signaling Technology, USA) and caspase 3 antibody (rabbit polyclonal antibody, Cell Signaling Technology, USA); 1248 Tyr-P-ErbB2, ErbB2, 1284 Tyr-P-ErbB4, T-ErbB4, and NRG-1 (rabbit polyclonal antibodies, Abcam, USA); GAPDH (mouse anti-human monoclonal antibody, Millipore, USA) and appropriate horseradish peroxidase-conjugated secondary antibody (ZSGB-BIO, China).

Techniques: Activation Assay, In Vivo, Western Blot